Home  |  Contact

Cellosaurus SUIT-2 (CVCL_3172)

[Text version]

Cell line name SUIT-2
Synonyms Suit-2; SUIT 2; SUIT2; Suit2
Accession CVCL_3172
Resource Identification Initiative To cite this cell line use: SUIT-2 (RRID:CVCL_3172)
Comments Part of: Cancer Cell Line Encyclopedia (CCLE) project.
Part of: COSMIC cell lines project.
Doubling time: ~38.2 hours (PubMed=3102439); 29.1 hours (PubMed=1391733); 15.64 hours (https://www.synapse.org/#!Synapse:syn2347014).
Microsatellite instability: Stable (MSS) (Sanger).
Omics: Deep exome analysis.
Omics: Deep RNAseq analysis.
Omics: DNA methylation analysis.
Omics: Metabolome analysis.
Omics: SNP array analysis.
Omics: Transcriptome analysis.
Sequence variations CDKN2A p.Glu69Ter (c.205G>T) (p.Gly83Val; c.248G>T) (PubMed=11787853).
KRAS p.Gly12Asp (c.35G>A) (PubMed=11787853; PubMed=21607521).
TP53 p.Arg273His (c.818G>A) (PubMed=11787853; PubMed=21607521).
Genome ancestry Source: PubMed=30894373

Origin% genome
African0
Native American1.31
East Asian, North81.51
East Asian, South17.16
South Asian0.02
European, North0
European, South0
Disease Pancreatic ductal adenocarcinoma (NCIt: C9120)
Derived from metastatic site: Liver.
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Children:
CVCL_B279 (S2-007)CVCL_B280 (S2-013)CVCL_B281 (S2-020)
CVCL_B282 (S2-028)CVCL_F971 (S2-CP8)CVCL_F972 (S2-VP10)
CVCL_B283 (S2/TXT)
Sex of cell Male
Age at sampling 73Y
Category Cancer cell line
STR profile Source(s): Cosmic-CLP; JCRB; PubMed=25877200; TKG

Markers:
AmelogeninX
CSF1PO11,12
D3S135816
D5S81811,12
D7S8209,11
D8S117914,15
D13S3179,11
D16S5399
D18S5116
D21S1129,30
FGA20,23
Penta D11
Penta E10
TH016
TPOX8,10
vWA16,17

Run an STR similarity search on this cell line
Web pages http://www.pawefish.path.cam.ac.uk/PancCellLineDescriptions/SUIT-2.html
Publications

PubMed=3102439; DOI=10.20772/cancersci1985.78.1_54
Iwamura T., Katsuki T., Ide K.
Establishment and characterization of a human pancreatic cancer cell line (SUIT-2) producing carcinoembryonic antigen and carbohydrate antigen 19-9.
Jpn. J. Cancer Res. 78:54-62(1987)

PubMed=1391733; DOI=10.1111/j.1440-1746.1992.tb01030.x
Iwamura T., Taniguchi S., Kitamura N., Yamanari H., Kojima A., Hidaka K., Setoguchi T., Katsuki T.
Correlation between CA19-9 production in vitro and histological grades of differentiation in vivo in clones isolated from a human pancreatic cancer cell line (SUIT-2).
J. Gastroenterol. Hepatol. 7:512-519(1992)

PubMed=21607521; DOI=10.3892/or.1.6.1223
Iguchi H., Morita R., Yasuda D., Takayanagi R., Ikeda Y., Takada Y., Shimazoe T., Nawata H., Kono A.
Alterations of the p53 tumor-suppressor gene and ki-ras oncogene in human pancreatic cancer-derived cell-lines with different metastatic potential.
Oncol. Rep. 1:1223-1227(1994)

PubMed=11169959; DOI=10.1002/1097-0215(200002)9999:9999<::AID-IJC1049>3.0.CO;2-C
Sirivatanauksorn V., Sirivatanauksorn Y., Gorman P.A., Davidson J.M., Sheer D., Moore P.S., Scarpa A., Edwards P.A.W., Lemoine N.R.
Non-random chromosomal rearrangements in pancreatic cancer cell lines identified by spectral karyotyping.
Int. J. Cancer 91:350-358(2001)

PubMed=11787853; DOI=10.1007/s004280100474
Moore P.S., Sipos B., Orlandini S., Sorio C., Real F.X., Lemoine N.R., Gress T.M., Bassi C., Kloppel G., Kalthoff H., Ungefroren H., Lohr M., Scarpa A.
Genetic profile of 22 pancreatic carcinoma cell lines. Analysis of K-ras, p53, p16 and DPC4/Smad4.
Virchows Arch. 439:798-802(2001)

PubMed=11854916; DOI=10.3748/wjg.v7.i6.855
Liu B., Staren E., Iwamura T., Appert H., Howard J.
Taxotere resistance in SUIT. Taxotere resistance in pancreatic carcinoma cell line SUIT 2 and its sublines.
World J. Gastroenterol. 7:855-859(2001)

PubMed=12800145; DOI=10.1002/gcc.10218
Adelaide J., Huang H.-E., Murati A., Alsop A.E., Orsetti B., Mozziconacci M.-J., Popovici C., Ginestier C., Letessier A., Basset C., Courtay-Cahen C., Jacquemier J., Theillet C., Birnbaum D., Edwards P.A.W., Chaffanet M.
A recurrent chromosome translocation breakpoint in breast and pancreatic cancer cell lines targets the neuregulin/NRG1 gene.
Genes Chromosomes Cancer 37:333-345(2003)

PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458
Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
Cancer Res. 70:2158-2164(2010)

PubMed=22460905; DOI=10.1038/nature11003
Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.K., Yu J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature 483:603-607(2012)

PubMed=25485619; DOI=10.1038/nbt.3080
Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z., Liu H., Degenhardt J., Mayba O., Gnad F., Liu J., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z.
A comprehensive transcriptional portrait of human cancer cell lines.
Nat. Biotechnol. 33:306-312(2015)

PubMed=26216984; DOI=10.1073/pnas.1501605112
Daemen A., Peterson D., Sahu N., McCord R., Du X., Liu B., Kowanetz K., Hong R., Moffat J., Gao M., Boudreau A., Mroue R., Corson L., O'Brien T., Qing J., Sampath D., Merchant M., Yauch R., Manning G., Settleman J., Hatzivassiliou G., Evangelista M.
Metabolite profiling stratifies pancreatic ductal adenocarcinomas into subtypes with distinct sensitivities to metabolic inhibitors.
Proc. Natl. Acad. Sci. U.S.A. 112:E4410-E4417(2015)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X., Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

PubMed=29444439; DOI=10.1016/j.celrep.2018.01.051
Yuan T.L., Amzallag A., Bagni R., Yi M., Afghani S., Burgan W., Fer N., Strathern L.A., Powell K., Smith B., Waters A.M., Drubin D., Thomson T., Liao R., Greninger P., Stein G.T., Murchie E., Cortez E., Egan R.K., Procter L., Bess M., Cheng K.T., Lee C.-S., Lee L.C., Fellmann C., Stephens R., Luo J., Lowe S.W., Benes C.H., McCormick F.
Differential effector engagement by oncogenic KRAS.
Cell Rep. 22:1889-1902(2018)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747
Dutil J., Chen Z., Monteiro A.N., Teer J.K., Eschrich S.A.
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Cancer Res. 79:1263-1273(2019)

PubMed=31068700; DOI=10.1038/s41586-019-1186-3
Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. III, Barretina J., Gelfand E.T., Bielski C.M., Li H., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R.
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Nature 569:503-508(2019)

Cross-references
Cell line collections JCRB; JCRB1094
TKG; TKG 0705
Cell line databases/resources CCLE; SUIT2_PANCREAS
Cell_Model_Passport; SIDM00371
Cosmic-CLP; 1240219
DepMap; ACH-000652
GDSC; 1240219
LINCS_LDP; LCL-1729
Lonza; 1079
Ontologies BTO; BTO:0003493
EFO; EFO_0006495
Biological sample resources BioSample; SAMN03472902
BioSample; SAMN10988018
Chemistry resources PharmacoDB; SUIT2_1507_2019
Gene expression databases ArrayExpress; E-MTAB-2706
ArrayExpress; E-MTAB-2770
ArrayExpress; E-MTAB-3610
GEO; GSM244426
GEO; GSM244427
GEO; GSM827218
GEO; GSM887657
GEO; GSM888749
GEO; GSM1588615
GEO; GSM1588627
GEO; GSM1670489
Other Wikidata; Q54970817
Polymorphism and mutation databases Cosmic; 710872
Cosmic; 755300
Cosmic; 808161
Cosmic; 918051
Cosmic; 1108340
Cosmic; 1320464
Cosmic; 1534322
Cosmic; 1995647
Cosmic; 2664046
IARC_TP53; 16745
LiGeA; CCLE_481
Entry history
Entry creation04-Apr-2012
Last entry updated06-Sep-2019
Version number26